Literature DB >> 2432019

Co-expression of human cancer-associated epitopes on mucin molecules.

M S Lan, R C Bast, M I Colnaghi, R C Knapp, D Colcher, J Schlom, R S Metzgar.   

Abstract

This work describes the immunochemical comparison of mucin-like high-molecular-weight glycoproteins associated with human malignancies that are defined by murine MAbs, DU-PAN-2, 19-9, OC-125, B 72.3, and Mov 2. These MAbs were originally elicited to human adenocarcinomas from different organ sites such as pancreas, colon, ovary, and breast, respectively. Although each antibody recognizes an antigen on tumors of the same type as the tumor used for immunization, there is often considerable cross-reactivity with adenocarcinomas from other organ sites. Additionally, these antigens have common properties of large molecular size, high carbohydrate content, and molecular size heterogeneity. Three antigens, CA 19-9, Mov 2, and DU-PAN-2, demonstrated size heterogeneity on agarose gel immunoblotting with their respective antibodies and gave different migration patterns from sera, bile, and pancreatic juice of patients with pancreatic adenocarcinoma. Data from inhibitory double determinant analyses indicated that the DU-PAN-2, CA 19-9, CA 125, TAG-72, and Mov 2 epitopes are distinct and non-cross-reactive. However, immunoblotting and affinity chromatography indicated that both 19-9 and DU-PAN-2 epitopes may be co-expressed on the same mucin molecule in varying proportions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2432019     DOI: 10.1002/ijc.2910390112

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Co-expression of X-hapten-like antigen and antigen YH206 on mucin molecules.

Authors:  Y Hinoda; K Imai; T Ban; F Itoh; A Yachi
Journal:  Gastroenterol Jpn       Date:  1991-02

2.  Expression of human tumor-associated antigens in pancreatic cancer induced in Syrian hamsters.

Authors:  Y Takiyama; H Egami; P M Pour
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

3.  Comparative studies on expression of CA 19-9 and DU-PAN-2 in pancreatic cancer tissue.

Authors:  H Takasaki; E Uchida; M A Tempero; D A Burnett; R S Metzgar; P M Pour
Journal:  Int J Pancreatol       Date:  1987 Oct-Dec

Review 4.  Composition and production of pancreatic tumor related antigens.

Authors:  H E Appert
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

5.  Comparative analysis of CA72-4, CA195 and carcinoembryonic antigen in patients with gastrointestinal malignancies.

Authors:  G V Kornek; D Depisch; H R Rosen; E M Temsch; W Scheithauer
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

6.  Expression of CA 72-4 (TAG-72) in the fluid contents of pancreatic cysts. A new marker to distinguish malignant pancreatic cystic tumors from benign neoplasms and pseudocysts.

Authors:  A J Alles; A L Warshaw; J F Southern; C C Compton; K B Lewandrowski
Journal:  Ann Surg       Date:  1994-02       Impact factor: 12.969

7.  Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma.

Authors:  F Tian; H E Appert; J Myles; J M Howard
Journal:  Ann Surg       Date:  1992-04       Impact factor: 12.969

8.  The patterns of coexpression of tumor-associated antigens CA 19-9, TAG-72, and DU-PAN-2 in human pancreatic cancer.

Authors:  I Toshkov; M Mogaki; K Kazakoff; P M Pour
Journal:  Int J Pancreatol       Date:  1994-04

9.  Detection of polymorphic epithelial mucins in the serum of systemic breast cancer patients using the monoclonal antibody, NCRC-11.

Authors:  M R Price; A J Clarke; J F Robertson; C O'Sullivan; R W Baldwin; R W Blamey
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

10.  Rat serum antibodies binding to high-molecular-weight glycoprotein(s) on syngeneic colon carcinomas, demonstrated by competition with rat monoclonal antibody.

Authors:  B Jansson; T Brodin; H O Sjögren
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.